药物评价表格:特利普林素 药物评价表格:特利普林素 药物评价表格
1Washington State University, Spokane, WA, USA.
Hospital pharmacy
|April 1, 2024
概括
单式专著服务为药学和治疗委员会提供每月的药物专著,包括利用评估和在线访问. 该服务有助于明智的药物决策和表单管理.
科学领域:
- 制药科学 制药科学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 药品和治疗 (P&T) 委员会需要及时,基于证据的信息来评估药物.
- 新药的批准和晚期试验需要持续评估药物的使用和安全性.
研究的目的:
- 描述表单式专著服务的特点和好处.
- 突出服务对参与表单管理和药物决策的医疗保健专业人员的实用性.
主要方法:
- 该服务每月提供5-6篇关于新药或晚期试验药物的详细专著.
- 包括药房和护理服务和药物使用评估/药物使用评估 (DUE/MUE) 的1页摘要专著.
主要成果:
- 订阅者可以获得针对P&T委员会量身定制的全面药物信息.
- 专著可以在网上获取,并且可以根据设施需求进行定制.
结论:
- 单式专著服务为基于证据的药物管理提供了宝贵的资源.
- 该服务支持知情决策,增强药房实践和患者护理.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Adrenergic Antagonists: ɑ and β-Receptor Blockers
443
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
443


